Park Ha Biological Technology Co., Ltd. BYAH
- Market cap
- $6.5M
- P/E
- —
Follow BYAH
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 1,480.00 | 54.80 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 2,760.00 | 16,596.00 |
High Price
|
|||
| — | — | — | — | — | — | — | 33 | 31 | 40 |
Employees
|
|||
| 0 | 0 | — | — | — | — | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 622 | 456 | — | — | — | — | 2 | 2 | 2 | 3 |
Revenue
|
|||
| 41.96% | 39.25% | — | — | — | — | 87.35% | 87.35% | 91.80% | 94.36% |
Gross Margin
|
|||
| (304) | (273) | — | — | — | — | 1 | (1) | 1 | (24) |
EBT
|
|||
| (48.87%) | (59.87%) | — | — | — | — | 48.05% | 0.00% | 33.31% | (953.90%) |
EBT Margin
|
|||
| 0 | 0 | — | — | — | — | 0 | 0 | 0 | (24) |
Net Income
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Depreciation
|
|||
| 0.00 | 0.00 | — | — | — | — | 0.00 | 39.35 | 38.11 | 34.30 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | 13.63 | 7.31 | (331.04) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 15.37 | 1.17 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | (1.37) | (1.21) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 14.00 | (0.04) |
Free CF/Sh
|
|||
| 0.00 | 0.00 | — | — | — | — | 0.00 | 16.20 | 24.10 | 54.28 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
PB Ratio
|
|||
| 0.00 | 0.00 | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales
|
|||
| (0.28) | (0.28) | — | — | — | — | (0.28) | (0.28) | (0.28) | (1.90) |
EV/FCF
|
|||
| — | — | — | — | — | — | — | (1) | 1 | 0 |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | 0 | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | (1) | 1 | 0 |
FCF
|
|||
| 256 | 56 | — | — | — | — | 1 | 1 | 1 | 4 |
Working Cap'
|
|||
| 1,262 | 370 | — | — | — | — | — | — | — | — |
Total Debt
|
|||
| 299 | (213) | — | — | — | — | (1) | (1) | (1) | (4) |
Net Debt
|
|||
| 1,090 | 553 | — | — | — | — | 1 | 1 | 2 | 4 |
Sh' Equity
|
|||
| (6.36%) | (11.98%) | — | — | — | — | 37.62% | 25.51% | 20.94% | (539.29%) |
ROA
|
|||
| (2.61%) | (15.07%) | — | — | — | — | 0.00% | 0.00% | 51.75% | (7,284.30%) |
ROIC
|
|||
| (94.39%) | 7,233.33% | — | — | — | — | (809.89%) | 0.00% | 38.01% | (885.83%) |
ROE
|
|||
Park Ha Biological Technology Co., Ltd. peers in Household & Personal Products
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BRSHF Bruush Oral Care Inc. | $8.7M | 0.0× | Compare |
| TANH Tantech Holdings Ltd. | $9.7M | 0.0× | Compare |
| ATTT Raytech Holding Limited | $15.9M | — | Compare |
| XAGE Longevity Health Holdings, Inc. | $1.6M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| DSY Big Tree Cloud Holdings Limited | $29.8M | 20.1× | Compare |
| UG United-Guardian, Inc. | $33.3M | 13.1× | Compare |
| GROV Grove Collaborative Holdings, Inc. | $44.8M | 0.0× | Compare |
| SLSN Solesence, Inc. | $57.2M | 0.0× | Compare |
Park Ha Biological Technology Co., Ltd. (BYAH) key facts
- Park Ha Biological Technology Co., Ltd. (BYAH) is a Household & Personal Products company in the Consumer Defensive sector, listed on Nasdaq.
- Park Ha Biological Technology Co., Ltd.’s revenue for fiscal 2025 (year ended October 2025) was $2.5 million, up 6.00% from fiscal 2024.
- As of September 25, 2026, BYAH traded at $2.77, a market capitalization of $6.5 million.
- Return on equity was −885.8% and debt-to-equity 0.00.
Park Ha Biological Technology Co., Ltd. (BYAH) Latest News
6 Jul
Park Ha Biological Technology Co., Ltd. receives official approval for its North American Amazon Store, initiating brand globalization. North American Amazon Store approval expands sales channels and supports international revenue growth.
5 Jul
Park Ha Biological Technology Co., Ltd. (BYAH) utilizes Amazon.com, Inc. (AMZN) e-commerce platform to support delivery expansion plans in India. India expansion through Amazon platform moderately strengthens BYAH operational reach and revenue potential.
1 Jul
Park Ha Biological Technology Co., Ltd. (BYAH) applied for membership in the Personal Care Products Council (PCPC) to align with international standards and advance its expansion into Amazon North America. PCPC membership application advances Park Ha Biological Technology's international standards compliance and Amazon expansion.
29 Jun
Park Ha Biological Technology Co., Ltd. (BYAH) announces cooperation with Amazon to enter the North American personal care sector and accelerate global strategy implementation. Amazon partnership drives major North American market entry and global expansion for the company.
23 Jun
Park Ha Biological Technology Co., Ltd. (BYAH) announces strategic partnership with Cloud Factory Technology Holdings Limited (02512.HK) to build an AI-driven ecosystem for the beauty industry. Strategic partnership targets AI ecosystem development in beauty sector representing major move likely to shift company trajectory.
12 Jun
Park Ha Biological Technology Co., Ltd. (BYAH) launches AI Nutritionist through strategic partnership to expand AI-powered skincare ecosystem. Strategic partnership and AI Nutritionist launch represent major product innovation expanding core AI skincare operations.
Park Ha Biological Technology Co., Ltd. (BYAH) forms strategic partnership with Star Plus Legend Group’s wholly-owned subsidiary to create AI-powered skincare and health ecosystem while broadening healthcare operations. Strategic alliance introduces AI technology to core skincare and health products, likely enhancing innovation and market expansion.
4 Feb
Park Ha Biological Technology Co., Ltd. (BYAH) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments within the company that are attracting attention from traders and investors alike. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.
28 Jan
Park Ha Biological Technology Co., Ltd. (BYAH) has successfully closed a public offering, raising US$2.45 million. The funds are intended to support the company's growth initiatives and enhance its operational capabilities. This financing is expected to bolster BYAH's position in the biotechnology sector and facilitate future projects. The public offering provides necessary capital that may enhance operational capabilities and support growth initiatives.
Park Ha Biological Technology Co., Ltd. (BYAH) has been identified as one of the most active stocks in the market, indicating heightened trading activity and investor interest. This surge in activity may reflect broader market trends or specific developments within the company that are attracting attention from traders and investors alike. Increased trading activity suggests a moderate influence on market sentiment and potential financial performance.
27 Jan
Park Ha Biological Technology Co., Ltd. has announced the pricing of a US$2.45 million best-efforts follow-on public offering. The offering is aimed at raising capital to support the company's growth initiatives and operational needs. The company plans to use the proceeds for general corporate purposes, which may include research and development, working capital, and other business activities. The follow-on public offering is expected to provide necessary capital for growth but its overall impact on the company's trajectory is limited.
30 Aug
Park Ha Biological Technology Co., Ltd. reported a loss of US$0.74 per share for the first half of 2025, a significant decline from a profit of US$0.002 per share in the same period of 2024. This downturn highlights challenges faced by the company in maintaining profitability amidst changing market conditions. The substantial loss per share indicates significant financial challenges that could impact investor sentiment and the company's future performance.
26 Jun
CEO Xiaoqiu Zhang of Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) has emerged as the most bullish insider, with his holdings experiencing a 35% increase in value last week, indicating strong confidence in the company's future prospects. The significant increase in insider holdings suggests strong confidence in the company's future performance and could positively influence investor sentiment.
30 Apr
Park Ha Biological Technology Co., Ltd. (PHH) is experiencing a surge in 2025 due to significant advancements in its biotechnology products and strategic partnerships that enhance its market position. The company has reported increased revenue projections driven by innovative research and development initiatives. Additionally, favorable regulatory changes are expected to boost its operational capabilities, attracting investor interest and improving overall market sentiment towards PHH. Significant advancements and strategic partnerships are likely to alter the company's trajectory and investor sentiment.
9 Mar
Park Ha Biological Technology Co., Ltd. (PHH) experienced a significant surge in stock price last week, attributed to positive developments in its research and product pipeline. The company announced promising results from clinical trials for its new biopharmaceuticals, which are expected to enhance its market position. Additionally, strategic partnerships with key industry players have been established, further bolstering investor confidence. Analysts predict that these advancements could lead to increased revenue and market share in the competitive biotechnology sector. Recent clinical trial successes and strategic partnerships are likely to significantly enhance the company's market position and investor sentiment.
6 Jan
D. Boral Capital has acted as the underwriter for Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) in its initial public offering, raising $4.8 million. This marks a significant milestone for PHH as it enters the public market, potentially enhancing its visibility and access to capital for future growth. The IPO provides PHH with capital for growth, which may moderately influence its financial performance and market positioning.
30 Dec
Park Ha Biological Technology Co., Ltd. has successfully closed its initial public offering (IPO), raising $4.8 million. The company plans to use the proceeds to enhance its research and development efforts, expand its product offerings, and strengthen its market presence. This IPO marks a significant milestone for PHH as it seeks to establish itself in the biotechnology sector. The IPO provides substantial funding for strategic initiatives that could significantly enhance the company's market position and growth trajectory.
26 Dec
Park Ha Biological Technology Co., Ltd. has announced the pricing of its initial public offering (IPO) at $4.8 million. The company aims to use the proceeds to enhance its research and development efforts, expand its product offerings, and strengthen its market position. The IPO is expected to provide the necessary capital for future growth and innovation. The IPO is a significant strategic move that could enhance the company's financial resources and market presence.